Overactive bladder: Achieving a differential diagnosis from other lower urinary tract conditions

International Journal of Clinical Practice

Volumn 59, Issue 7, 2005, Pages 825-830

  Nitti, Victor ^a,b   Taneja, S ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Bladder cancer; Overactive bladder; Urinary tract infection

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; TAMSULOSIN; TERAZOSIN; TOLTERODINE;

ADAPTIVE BEHAVIOR; ALGORITHM; BEHAVIOR THERAPY; BLADDER CANCER; CLINICAL PRACTICE; CLINICAL TRIAL; COPING BEHAVIOR; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DRUG SELECTIVITY; HEMATURIA; HUMAN; OVERACTIVE BLADDER; PELVIC FLOOR MUSCLE TRAINING; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; SYMPTOMATOLOGY; URGE INCONTINENCE; URINALYSIS; URINARY FREQUENCY; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URINARY URGENCY; URINE CULTURE; XEROSTOMIA; BLADDER DISEASE; BLADDER TUMOR; METHODOLOGY; MICTURITION DISORDER;

ALGORITHMS; DIAGNOSIS, DIFFERENTIAL; HEMATURIA; HUMANS; URINALYSIS; URINARY BLADDER DISEASES; URINARY BLADDER NEOPLASMS; URINARY TRACT INFECTIONS; URINATION DISORDERS;

EID: 25444463849     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2005.00490.x     Document Type: Review

References (43)

1. Thom D. Variation in estimates of urinary incontinence prevalence in the community: Effects of differences in definition, population characteristics, and study type. J Am Geriatr Soc 1998; 46: 473-80.
2. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6.
3. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36.
4. Abrams P, Kelleher CJ, Lerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care 2000; 6 (Suppl.): S580-S590.
5. Davila GW, Neimark M. The overactive bladder: Prevalence and effects on quality of life. Clin Obstet Gynecol 2002; 45: 173-81.
6. Diokno AC. Epidemiology and psychosocial aspects of incontinence. Urol Clin North Am 1995; 22: 481-5.
7. Liberman JN, Hunt TL, Stewart WF et al. Health-related quality of life among adults with symptoms of overactive bladder: Results from a US community-based survey. Urology 2001; 57: 1044-50.
8. Stewart WF, McGhan WF, Offerdahl T, Corey R. Overactive bladder patients and the role of the pharmacist. J Am Pharm Assoc (Wash) 2002; 42: 469-76.
9. Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing 1997; 26: 367-74.
10. Wagner TH, Hu TW. Economic costs of urinary incontinence in 1995. Urology 1998; 51: 355-61.
11. Goepel M, Hoffmann JA, Piro M et al. Prevalence and physician awareness of symptoms of urinary bladder dysfunction. Eur Urol 2002; 41: 234-9.
12. Milsom I, Stewart W, Thuroff J. The prevalence of overactive bladder. Am J Manag Care 2000; 6 (Suppl.): S565-S573.
13. Schappert SM. Ambulatory care visits to physician offices, hospital outpatient departments and emergency departments: United States, 1997. Vital Health Stat 13 1999; 143: I-iv, 1-39.
14. Foxman B. Epidemiology of urinary tract infections: Incidence, morbidity and economic costs. Dis Mon 2003; 49: 53-70.
15. Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin Surg Oncol 1997; 13: 291-8.
16. Borden LS Jr, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol 2003; 15: 227-33.
17. Grossfeld GD, Wolf JS, Litwin MS et al. Asymptomatic microscopic hematuria in adults: Summary of the AUA best practice policy recommendations. Am Fam Physician 2001; 63: 1145-54.
18. de Braud F, Maffezzini M, Vitale V et al. Bladder cancer. Crit Rev Oncol Hematol 2002; 41: 89-106.
19. Bent S, Nallamothu BK, Simel DL et al. Does this woman have an acute uncomplicated urinary tract infection? JAMA 2002; 287: 2701-10.
20. National Kidney and Urologic Diseases Information Clearing House (NKUDIC). Urinary tract infections in adults. NIH publication no. 04-2097; November 2003. Retrieved from http://www.kidney.niddk.nih.gov; accessed May 2004.
21. Lammers RL, Gibson S, Kovacs D et al. Comparison of test characteristics of urine dipstick and urinalysis at various test cutoff points. Ann Emerg Med 2001; 38: 505-12.
22. Leman P. Validity of urinalysis and microscopy for detecting urinary tract infection in the emergency department. Eur J Emerg Med 2002; 9: 141-7.
23. Buntinx F, Wauters H. The diagnostic value of macroscopic haematuria in diagnosing urological cancers: A meta-analysis. Fam Pract 1997; 14: 63-8.
24. Grossfeld GD, Carroll PR. Evaluation of asymptomatic microscopic hematuria. Urol Clin North Am 1998; 25: 661-76.
25. Britton JP, Dowell AC, Whelan P, Harris CM. A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol 1992; 148: 788-90.
26. Mayfield MP, Whelan P. Bladder tumours detected on screening: Results at 7 years. Br J Urol 1998; 82: 825-8.
27. Khan MA, Shaw G, Paris AM. Is microscopic haematuria a urological emergency? BJU Int 2002; 90: 355-7.
28. Messing EM, Young TB, Hunt VB et al. Hematuria home screening: Repeat testing results. J Urol 1995; 154: 57-61.
29. Payne CK. Epidemiology, pathophysiology, and evaluation of urinary incontinence and overactive bladder. Urology 1998; 51: 3-10.
30. Wein AJ, Rovner ES. The overactive bladder: An overview for primary care health providers. Int J Fertil Womens Med 1999; 44: 56-66.
31. Nitti VW. Overactive bladder. Strategies for effective evaluation and management. Contemp Urol 2001; (Suppl.): 14-21.
32. Clemett D, Jarvis B. Tolterodine. A review of its use in the treatment of overactive bladder. Drugs Aging 2001; 18: 277-304.
33. Gleason DG, Susset J, White C et al. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology 1999; 54: 420-3.
34. Malone-Lee JG, Walsh JB, Maugourd M et al. Tolterodine: A safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001; 49: 700-5.
35. Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002; 50: 799-807.
36. Diokno AC, Appell RA, Sand PK et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: Results of the OPERA trial. Mayo Clin Proc 2003; 78: 687-95.
37. Malone-Lee JG. The efficacy, tolerability and safety profile of tolterodine in the treatment of overactive/unstable bladder. Rev Contemp Pharmacother 2000; 11: 29-42.
38. Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: The antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin 2002; 18: 177-84.
39. Staskin DR, Wein AJ, Andersson KE et al. Overview consensus statement. Urology 2002; 60 (Suppl.): 1-6.
40. Mattiasson A, Blaakaer J, Høye K and the tolterodine Sandinavian Study Group. Simplified bladder training augments the effectiveness of tolterodine in patients with overactive bladder. BJU Int 2003; 91: 54-60.
41. Visco AG, Weidner AC, Cundiff GW, Bump RC. Observed patients compliance with a structured outpatient bladder retraining program. Am J Obstet Gynecol 1999; 181: 1392-4.
42. Fantl JA, Wyman JF, Mclish DK et al. Efficacy of bladder training in older women with urinary incontinence. JAMA 1991; 265: 609-13.
43. Siami P, Seidman LS, Lama D. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: The speed of onset of therapeutic assessment trial (STAT). Clin Ther 2002; 24: 616-28.